RPTP Raptor Pharmaceuticals Corp

RAPTOR PHARMACEUTICAL CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.:

  • Do you own shares of Raptor Pharmaceutical Corp. (NASDAQ GM: RPTP)?
  • Did you purchase any of your shares prior to September 12, 2016?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (NASDAQ GM: RPTP) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Horizon Pharma plc (“Horizon”) (NASDAQ GS: HZNP), in a transaction valued at approximately $800 million.

Click here to learn more: http://rigrodskylong.com/investigations/raptor-pharmaceutical-corp-rptp.

Under the terms of the agreement, shareholders of Raptor will receive $9.00 in cash for each share of Raptor common stock.

The investigation concerns whether Raptor’s board of directors failed to adequately shop the Company and obtain the best possible value for Raptor shareholders before entering into an agreement with Horizon.

If you own the common stock of Raptor and purchased your shares before September 12, 2016, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to [email protected], or at: http://rigrodskylong.com/investigations/raptor-pharmaceutical-corp-rptp.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

EN
12/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Raptor Pharmaceuticals Corp

 PRESS RELEASE

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Propo...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) (“Raptor” or the “Company”) relating to the proposed buyout of Raptor by Horizon Pharma plc. Under the terms of the agreement, Raptor shareholders are anticipated to receive $9.00 in cash for each share of Raptor common stock held. The ...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regar...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Raptor Pharmaceutical Corp. (“Raptor”) (NASDAQ: RPTP) stock prior to September 12, 2016. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Raptor to Horizon Pharma Plc (NASDAQ: HZNP) for $9.00 per share. To learn more about the action and your rights, go to: http://zlk.9nl.com/raptor-pharmaceutical-rptp ...

 PRESS RELEASE

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) (“Raptor” or the “Company”) relating to the proposed buyout of Raptor by Horizon Pharma Plc. Under the terms of the agreement, Raptor shareholders are anticipated to receive $9.00 in cash for each share of Raptor common stock held. The ...

 PRESS RELEASE

RAPTOR PHARMACEUTICAL CORP. SHAREHOLDER ALERT: Former SEC Attorney Wil...

DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Raptor Pharmaceutical Corp. (“Raptor”) (NasdaqGM: RPTP) concerning the sale to Horizon Pharma plc. Under the terms of the agreement, Raptor shareholders will only receive $9.00 for each share owned, which is virtually no premium over the 52-week high and lower than at least one analyst’s estimated value of $...

 PRESS RELEASE

RAPTOR PHARMACEUTICAL CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Raptor Pharmaceutical Corp. (NASDAQ GM: RPTP)? Did you purchase any of your shares prior to September 12, 2016? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (NA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch